Skip to main content

Search for new therapeutic agents against complicated obesity by reprofiling existing drugs

Objetivo

Obesity is one of the most serious and fast-growing health problem in the European Union, and a leading cause of diabetes. The main barrier for approval of an anti-obesity drug is the safety requirements. We propose to overcome this barrier by discovering phenotypes and biomarkers that identify subsets of patients with safe and efficacious responses to drugs, and by identifying new indications of existing drugs with proven safety profiles. To be approved, anti-obesity drugs need to show a decrease in abdominal fat. We focus on approaches targeting directly abdominal fat cells. In the last years only the cannabinoid CB1 receptor antagonist Rimonabant has been approved as a therapeutic agent to combat complicated obesity. Research performed with this drug has clearly revealed a role for the endogenous cannabinoid system in controlling energy homeostasis. However, its utility is limited to a restricted set of patients. A new phenotype and/or biomarker may identify responsive patients with good safety profiles. This proposal aims to discover novel or improved treatments in the shortest possible timeframe through three synergistic Specific Aims: 1) Clinical phenotyping of obese patients to identify those that would benefit from existing therapies such as Rimonabant. 2) Discover biomarkers for subsets of obese patients that may correlate with therapeutical outcomes. These biomarkers will be discovered by a novel approach called Combinatorial Cytomic Biomarkers developed by OrphaMed, applied to cells from two physiologically interlinked sources: blood and abdominal-fat samples, extracted from the above phenotyped patients. 3) Identify new indications of existing drugs, alone or in combination, with potential anti-obesity efficacy by lowering the fat content and the glucose uptake of abdominal fat cells, which would be expected to improve carbohydrate/lipid metabolism and lower body weight, extracted from the above phenotyped patients. This will be accomplished by screening approximately 2.000 known drugs against these fat cells using the novel technology platform “ExviTech” from OrphaMed. Candidates would be evaluated in animal models of obesity.

Convocatoria de propuestas

FP7-HEALTH-2007-B
Consulte otros proyectos de esta convocatoria

Coordinador

FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD
Dirección
Calle Severo Ochoa 35, Parque Tecnologico De Andalucia
29580 Malaga
España

Ver en el mapa

Tipo de actividad
Research Organisations
Contacto administrativo
Fernando Rodriguez De Fonseca (Dr.)
Aportación de la UE
€ 594 005

Participantes (6)

VIVIA BIOTECH S.L.
España
Aportación de la UE
€ 2 723 786
Dirección
C Santiago Grisolia 2 Oficina 205
28760 Tres Cantos Madrid

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Olivia De La Lama Noriega (Ms.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Francia
Aportación de la UE
€ 505 440
Dirección
Rue De Tolbiac 101
75654 Paris

Ver en el mapa

Tipo de actividad
Research Organisations
Contacto administrativo
Giovanni Marsicano (Dr.)
JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Alemania
Dirección
Saarstrasse 21
55122 Mainz

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Beat Lutz (Prof.)
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
Italia
Aportación de la UE
€ 508 860
Dirección
Via Zamboni 33
40126 Bologna

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Alessandra Malavolta (Dr.)
UNIVERSIDAD DE SANTIAGO DE COMPOSTELA
España
Aportación de la UE
€ 505 919
Dirección
Colexio De San Xerome Praza Do Obradoiro S/n
15782 Santiago De Compostela

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Fernando Sedano Arnaez (Dr.)
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ
Alemania
Aportación de la UE
€ 561 402
Dirección
Langenbeckstrasse 1
55131 Mainz

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Uta Veith (Dr.)